• Title/Summary/Keyword: Three-dimensional ultrasonography

Search Result 13, Processing Time 0.02 seconds

Measurement of S1 foramen depth for ultrasound-guided S1 transforaminal epidural injection

  • Ye Sull Kim;SeongOk Park;Chanhong Lee;Sang-Kyi Lee;A Ram Doo;Ji-Seon Son
    • The Korean Journal of Pain
    • /
    • v.36 no.1
    • /
    • pp.98-105
    • /
    • 2023
  • Background: Ultrasound-guided first sacral transforaminal epidural steroid injection (S1 TFESI) is a useful and easily applicable alternative to fluoroscopy or computed tomography (CT) in lumbosacral radiculopathy. When a needle approach is used, poor visualization of the needle tip reduces the accuracy of the procedure, increasing its difficulty. This study aimed to improve ultrasound-guided S1 TFESI by evaluating radiological S1 posterior foramen data obtained using three-dimensional CT (3D-CT). Methods: Axial 3D-CT images of the pelvis were retrospectively analyzed. The radiological measurements obtained from the images included 1st posterior sacral foramen depth (S1D, mm), 1st posterior sacral foramen width (S1W, mm), the angle of the 1st posterior sacral foramen (S1A, °), and 1st posterior sacral foramen distance (S1ds, mm). The relationship between the demographic factors and measured values were then analyzed. Results: A total of 632 patients (287 male and 345 female) were examined. The mean S1D values for males and females were 11.9 ± 1.9 mm and 10.6 ± 1.8 mm, respectively (P < 0.001); the mean S1A 28.2 ± 4.8° and 30.1 ± 4.9°, respectively (P < 0.001); and the mean S1ds, 24.1 ± 2.9 mm and 22.9 ± 2.6 mm, respectively (P < 0.001); however, the mean S1W values were not significantly different. Height was the only significant predictor of S1D (β = 0.318, P = 0.004). Conclusions: Ultrasound-guided S1 TFESI performance and safety may be improved with adjustment of needle insertion depth congruent with the patient's height.

A Study on the Development of Ultrasonography Guide using Motion Tracking System (이미지 가이드 시스템 기반 초음파 검사 교육 기법 개발: 예비 연구)

  • Jung Young-Jin;Kim Eun-Hye;Choi Hye-Rin;Lee Chae-Jeong;Kim Seo-Hyeon;Choi Yu-Jin;Hong Dong-Hee
    • Journal of the Korean Society of Radiology
    • /
    • v.17 no.7
    • /
    • pp.1067-1073
    • /
    • 2023
  • Breast cancer is one of the top three most common cancers in modern women, and the incidence rate is increasing rapidly. Breast cancer has a high family history and a mortality rate of about 15%, making it a high-risk group. Therefore, breast cancer needs constant management after an early examination. Among the various equipment that can diagnose cancer, ultrasound has the advantage of low risk and being able to diagnose in real time. In addition, breast ultrasound will be more useful because Asian women's breasts are denser and less sensitive. However, the results of ultrasound examinations vary greatly depending on the technology of the examiner. To compensate for this, we intend to incorporate motion tracking technology. Motion tracking is a technology that specifies and analyzes a location according to the movement of an object in a three-dimensional space. Therefore, real-time control is possible, and complex and fast movements can be recorded in real time. We would like to present the production of an ultrasound examination guide using these advantages.

The Change of Facial Contouring after Unilateral Injection of Botulinum Toxin in Unilateral Masseter Hypertrophy Patients (편측성 교근비대 환자에서 편측 보툴리눔 독소 주사 후 안모의 변화)

  • Cha, Yu-Rim;Kim, Young-Gun;Kim, Ji-Hyun;Shim, Young-Joo;Kim, Seong-Taek
    • Journal of Dental Rehabilitation and Applied Science
    • /
    • v.27 no.2
    • /
    • pp.247-251
    • /
    • 2011
  • Botulinum toxin type A (BoNT-A) is used for treating bilateral masseter hypertrophy since 1994. Recently there have been more clinical studies in this area, with some authors reporting that BoNT-A can reduce the size of the masseter muscle, as documented by photography, ultrasonography, computed tomography, and 3D(three dimensional) laser scan. However, earlier studies were only for bilateral masseter hypertrophy cases, not for unilateral masseter hypertrophy cases. The aim of this study was to use 3D laser scanning to evaluate changes in the external facial contour induced by unilateral BoNT-A injection. BoNT-A was injected into hypertrophic masseter muscle unilaterally in 10 patients with asymmetric masseter hypertrophy. The clinical effects of unilaterally injected BoNT-A were evaluated before the injection and 4, 8, and 12weeks after the injection using 3D laser scan. And the mean values of both sides (injection and non-injection sides) were compared with. At injection side, mean values of the volume and the bulkiest height at each time point diminished significantly between pre-injection and 4, 8, and 12weeks post-injection. At non-injection side, in contrast, mean values of the volume and the bulkiest height diminished also but less than that of injected side, and there was no statistical significance. In this limited study, we concluded that the unilaterally BoNT-A injection side showed greater mean values of the reduction of muscle volume than non-injection side at 4, 8, and 12 weeks after the injection.